



ESOCAP ONE OF JUST A HANDFUL OF COMPANIES SELECTED TO PRESENT AT THE BIO-EUROPE CONFERENCE START UP SPOTLIGHT ON MARCH 26, 2019

Basel, Switzerland, March 8, 2019

EsoCap AG is one of just a handful of companies in the area of biotech and medtech selected to present at the Bio-Europe conference start-up spotlight on March 26, 2019 in Vienna.

“We are very excited to present at the Bio-Europe conference start-up spotlight”, said Isabelle Racamier, EsoCap AG CEO. “This is a recognition of the innovative nature of our technology and business strategy.” At the moment there are insufficient therapeutic options for esophageal diseases. Up to now, local treatment of esophagitis has not been possible due to the ultra-short clearance time in the esophagus. There is no single medication globally approved for topical administration in the esophagus.

Our unique topical application technology may be beneficial in at least 6 indications affecting 370 million patients, including gastroenterology, oncology and orphan diseases. “The EsoCap smart application technology is a paradigm shift for the effective and safe treatment of esophageal diseases” said Dr. Peter Stangier, EsoCap AG Director Strategic Planning.

About EsoCap AG

EsoCap is a Swiss privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique topical drug delivery platform.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

Contact:

EsoCap AG

Malzgasse 9

4052 Basel

Switzerland

isabelle.racamier@esocapbiotech.com